ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 491,40
0,23%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ocean Biomedical Inc (OCEA)

  7. Ocean Biomedical Inc (OCEA) Actualités

OCEA

Ocean Biomedical (OCEA)

Ocean Biomedical Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OCEA
DateHeureSourceTitreSymboleSociété
05/06/202413h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024NASDAQ:OCEAOcean Biomedical Inc
30/05/202413h44GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-QNASDAQ:OCEAOcean Biomedical Inc
16/05/202414h01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe DiseaseNASDAQ:OCEAOcean Biomedical Inc
24/04/202422h51GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-KNASDAQ:OCEAOcean Biomedical Inc
28/03/202413h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASLNASDAQ:OCEAOcean Biomedical Inc
08/03/202423h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCEAOcean Biomedical Inc
29/02/202414h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver MeetingNASDAQ:OCEAOcean Biomedical Inc
14/02/202400h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCEAOcean Biomedical Inc
05/12/202314h15GlobeNewswire Inc.Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 AntibodyNASDAQ:OCEAOcean Biomedical Inc
15/11/202312h20Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:OCEAOcean Biomedical Inc
14/11/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
26/10/202311h30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
26/10/202311h30PR Newswire (US)Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus InfectionNASDAQ:OCEAOcean Biomedical Inc
24/10/202312h30GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan KurtisNASDAQ:OCEAOcean Biomedical Inc
17/10/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion TherapeuticsNASDAQ:OCEAOcean Biomedical Inc
12/10/202314h01GlobeNewswire Inc.Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients WorldwideNASDAQ:OCEAOcean Biomedical Inc
12/10/202314h01PR Newswire (US)Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwideNASDAQ:OCEAOcean Biomedical Inc
04/10/202322h56GlobeNewswire Inc.Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master FundNASDAQ:OCEAOcean Biomedical Inc
04/10/202314h01GlobeNewswire Inc.Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 MillionNASDAQ:OCEAOcean Biomedical Inc
03/10/202320h30GlobeNewswire Inc.Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing PartnerNASDAQ:OCEAOcean Biomedical Inc
03/10/202314h01GlobeNewswire Inc.Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung CancersNASDAQ:OCEAOcean Biomedical Inc
14/09/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Will Host an R&D Update Today on Malaria, and Fibrosis Programs with Scientific Co-founders Jack A. Elias, MD, and Jonathan Kurtis, MD PhD.NASDAQ:OCEAOcean Biomedical Inc
29/08/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Announces New Patent for Anti-Fibrosis Discovery with Allowance in Alcoholic Liver Disease and Multiple Fibrotic Conditions, Leading Causes of Death in the U.S.NASDAQ:OCEAOcean Biomedical Inc
16/08/202323h10Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:OCEAOcean Biomedical Inc
10/08/202314h01GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Provides Latest Updates on its Broad Programs in Malaria, Fibrosis, and Multiple CancersNASDAQ:OCEAOcean Biomedical Inc
09/08/202314h31GlobeNewswire Inc.Ocean Biomedical (NASDAQ: OCEA) Share Price Target Now Averaging $18.21, Based on Research and Development Progress in Three Promising Programs Generating Novel Treatment Candidates for Cancer, Malaria, and Fibrosis.NASDAQ:OCEAOcean Biomedical Inc
04/08/202323h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCEAOcean Biomedical Inc
01/08/202314h01GlobeNewswire Inc.Ocean Biomedical, Inc. (NASDAQ: OCEA) Celebrates 95% Lung Cancer Tumor Reduction Results on World Lung Cancer DayNASDAQ:OCEAOcean Biomedical Inc
24/07/202323h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCEAOcean Biomedical Inc
11/07/202314h01GlobeNewswire Inc.Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria ChallengesNASDAQ:OCEAOcean Biomedical Inc
 Showing the most relevant articles for your search:NASDAQ:OCEA

Dernières Valeurs Consultées

LSE
82TP
Arran 2.bb56a
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés